secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aquestive Therapeutics, Inc. (AQST)
CIK:        0001398733
Form:       8-K
Filed at:   2025-08-15T23:59:59+00:00
Accession:  0001140361-25-031374
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aquestive prices $85M common stock offering of 21.25M shares at $4.00/share
---------------------------------------------------------------------------

- Offers 21.25M shares at $4.00/share; expected gross proceeds $85M, closing Aug 15, 2025.
- Proceeds to primarily fund launch/commercialization of Anaphylm (epinephrine sublingual film) pending FDA approval.
- Offering led by RTW Investments; includes Samsara BioCapital, EcoR1 Capital, Perceptive Advisors, others.
- Joint bookrunning managers: Leerink Partners, Cantor, Oppenheimer; H.C. Wainwright lead manager.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1398733/000114036125031374/0001140361-25-031374-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1398733/000114036125031374/ef20053945_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-031374

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer